Personalis' NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO
The results were presented yesterday by Jyoti Mayadev, MD, from the University of California San Diego, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Ultrasensitive detection and tracking of circulating tumor DNA (ctDNA) and association with relapse and survival in locally advanced cervical cancer (LACC): Phase 3 CALLA trial analyses." The results from this study were also simultaneously published in the journal Annals of Oncology.
Samples were analyzed from patients with cervical cancer who had enrolled in the original CALLA clinical trial. In this new study analysis, NeXT Personal was used to look for small traces of ctDNA in blood samples from a cohort of 186 patients with locally advanced cervical cancer. Dr. Mayadev's team found that overall ctDNA levels after chemoradiotherapy (CRT) treatment were strongly predictive of risk of cervical cancer progression.
"Despite standard chemoradiotherapy, up to half of patients with locally advanced cervical cancer relapse, underscoring the urgent need for better prognostic tools. In the CALLA phase 3 study, ultrasensitive, tumor-informed ctDNA analysis emerged as a powerful predictor of progression and survival—detecting relapse up to ~16 months before imaging. These findings highlight ctDNA's potential to guide treatment decisions and personalize care in high-risk cervical cancer," said Dr. Mayadev.
Key findings presented:
Detection of ctDNA following CRT was independently prognostic of patient outcomes.
Risk of progression and death were at least 95% lower for patients where ctDNA was not detected ~3 months after completing CRT.
Detection of ctDNA after CRT was associated with high subsequent risk of disease progression, and was detected a median of ~5 months and up to ~16 months earlier than by imaging scans.
High ctDNA levels (≥ median) at baseline was associated with higher risk of progression and death.
"We are excited to see the results presented for NeXT Personal in this large phase 3 study in cervical cancer," said Richard Chen, MD, Chief Medical Officer and Executive Vice President, R&D at Personalis. "Cervical cancer is the fourth most common cancer for women globally, resulting in hundreds of thousands of deaths each year. The new results show the strong potential for an ultrasensitive MRD test like NeXT Personal to inform treatment for cervical cancer patients."
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release that are not historical are "forward-looking statements" within the meaning of U.S. securities laws, including statements relating to the attributes, advantages, sensitivity, clinical relevance or importance of the NeXT Personal test. Such forward-looking statements involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the ability of NeXT Personal to detect small traces of ctDNA, detect residual or recurrent cancer early (including detection earlier than standard of care imaging), monitor or predict a patient's response to therapy or risk of cancer recurrence, accurately predict clinical outcomes for cancer patients, or impact cancer care or management (including for escalation or de-escalation of treatment), or to the clinical adoption or use of, or the ability of Personalis to obtain Medicare coverage or reimbursement for, the NeXT Personal test, or to the sufficiency of the publication and study results described in this press release to support such adoption, use, coverage or reimbursement. These and other potential risks and uncertainties that could cause actual results to differ materially from the results predicted in these forward-looking statements are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Personalis' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC on May 6, 2025. All information provided in this release is as of the date of this press release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Personalis undertakes no duty to update this information unless required by law.
Not affiliated with or endorsed by ASCO.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603114064/en/
Contacts
Investors: Caroline Cornerinvestors@personalis.com 415-202-5678
Media Contact pr@personalis.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Up Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher?
Tilray's stock has been rallying since the start of July despite an absence of significant news. Investors have often bought the stock on hopes that the U.S. marijuana market will open up. However, that doesn't appear to be on the horizon, and Tilray faces many challenges ahead. 10 stocks we like better than Tilray Brands › The S&P 500 index has been hitting record highs and may be running out of room to rise a whole lot more. For investors, now may be an opportune time to pay attention to stocks which may be poised for greater gains and which haven't been doing particularly well. One notable stock of late has been Tilray Brands (NASDAQ: TLRY), which has a diverse business centering around cannabis and beverages. While it hasn't been a strong buy at all this year (it's down more than 50% year to date), it has been picking up steam of late. As of Friday, it was up around 40% in the past month. Could this struggling stock be on track for an even bigger rally ahead, or could this be just a short-lived bump-up in value? The big reason to invest into Tilray is if you're bullish on marijuana legalization in the U.S. If that happens, the Canadian-based cannabis producer would have a way to enter a huge, lucrative market, enabling it to drastically grow its sales. But with nothing seemingly happening on that front of late, growth investors have, for the most part, avoided it. As of the end of June, the stock was down a whopping 69% as it looked poised for yet another disastrous year. In 2024, the pot stock fell by more than 40% after declining by nearly 15% the year before that. But in the first few days of July, Tilray's stock started to rally. And on July 9 it hit an intra-day high of $0.70 -- levels it hadn't hit since March. The company, however, hasn't released any major news of late, and its latest quarterly report isn't coming out until later this month, on July 28. Investors buying Tilray may simply have been pivoting to cheaper stocks, especially with the markets up around record levels and many top-performing stocks looking expensive. Tilray is also a popular stock with retail investors, and when its momentum picks up, for any reason, that can lead to a snowball effect. The problem with Tilray is that it's struggling to find ways to grow its business in a sustainable way. It's leaned on acquisitions of craft brewers in the past as a way to expand its operations. But acquisitions often lead to just temporary, short-term boosts. Tilray's sales growth rate has been underwhelming of late. For the period ended Feb. 28, its net revenue totaled $186 million and was down more than 1% year over year. Without a U.S. cannabis market to tap into right now, and the company incurring a net loss of more than $913 million over the past three quarters, there isn't an overwhelming reason for investors to want to take a chance on the stock, even if it may look cheap. Tilray's stock got a boost recently despite no significant developments. That's a sign of just how dangerously speculative and unpredictable the stock can be. While it may be tempting to buy into a stock that's suddenly taking off, this type of rally usually doesn't end up being sustainable. Consider that over the past five years, shares of Tilray have fallen an incredible 93%. Although there may be brief spikes along the way, it's been an incredibly strong, downward trend for the stock. And without a reason to expect that things will get better for Tilray anytime soon, investors may still be better off steering clear of this highly risky and volatile stock. Before you buy stock in Tilray Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tilray Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you'd have $680,559!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,670!* Now, it's worth notingStock Advisor's total average return is1,053% — a market-crushing outperformance compared to180%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025 David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. Up Around 40% in Just the Past Month, Could This Red-Hot Growth Stock Rally Even Higher? was originally published by The Motley Fool
Business Wire
25 minutes ago
- Business Wire
Elucid Applauds CMS Inclusion of Coronary CTA with Plaque Analysis in 2026 Proposed Medicare Physician Fee Schedule
BOSTON--(BUSINESS WIRE)-- Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis to drive patient-specific therapeutic decisions, today released a statement commending U.S. Centers for Medicare & Medicaid Services (CMS) for the inclusion of a Category I CPT code for coronary plaque analysis and a national Medicare average payment amount of over $1,000, pending the final Medicare Physician Fee Schedule (PFS) ruling, which will come out in November. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. Cardiovascular disease continues to be a critical public health issue in the United States, remaining the leading cause of death nationwide. In 2022, heart disease claimed over 700,000 lives—nearly 1 in every 5 deaths—underscoring the urgent need for early detection and intervention. 1 Despite advances, many high‑risk patients remain undiagnosed until they experience serious cardiac events. The proposed rule by CMS marks a significant step toward broader access to innovative, evidence-based imaging tools that help identify high-risk cardiovascular patients earlier and more accurately. 'Elucid is encouraged by the addition of the Category I CPT code and payment level for coronary CTA with plaque analysis in the Calendar Year 2026 Medicare Physician Fee Schedule proposed rule,' said Elucid CEO Kelly Huang, PhD. 'We commend CMS for ensuring that the proposed payment level reflects the clinical value, technological investment, and expertise needed to perform this service, enabling Medicare beneficiaries to access this technology.' Coronary computed tomography angiography (CTA) with plaque analysis offers invaluable insights into plaque burden, composition, and morphology, enabling earlier and more accurate identification of high-risk patients who may benefit from targeted medical therapy and lifestyle interventions. Numerous studies have demonstrated that such non-invasive imaging enhances risk stratification and clinical decision-making while reducing the need for more invasive and costly diagnostic procedures. 'Elucid remains optimistic as we await the final publication of the code and payment, effective January 1, 2026,' said Huang. 'We recognize the efforts of societies and physician organizations collaborating with the AMA and CMS to reach an appropriate payment level. We look forward to continued cooperation to enhance patient outcomes and access.' The proposed rule outlines payment policies and rates for services furnished under Medicare Part B. The inclusion of coronary CTA with plaque analysis represents a significant advancement for precision cardiovascular care. It follows a new CMS rule that went into effect January 1, 2025, which doubled the amount paid to hospitals and outpatient clinics who perform cardiac CT scans from $175 to $357. This has already allowed more hospitals, particularly those in non-urban areas, to be able to offer this service, reducing disparities in care. About Elucid Elucid is a Boston-based AI medical technology company dedicated to developing technology designed to provide physicians with a more precise view of atherosclerosis (coronary plaque buildup), the root cause of cardiovascular disease. The company's PlaqueIQ TM image analysis software is designed to help physicians prioritize and personalize treatment based on actual disease, rather than population-based risk of disease. PlaqueIQ includes the only FDA-cleared computed tomography angiography (CTA) algorithm that objectively quantifies plaque morphology validated against ground truth histology, the gold standard for characterization of plaque, as indicated by renowned pathologists. PlaqueIQ equips physicians with critical information regarding the type and amount of plaque in arteries that can lead to heart attack and stroke. Elucid is also pursuing an indication for FFR CT, derived from its plaque algorithm, to help identify coronary blockages and the extent of ischemia non-invasively. For more information, visit
Hamilton Spectator
28 minutes ago
- Hamilton Spectator
S&P/TSX composite down amid fresh inflation data in Canada and the U.S.
TORONTO - Canada's main stock index fell more than 140 points to finish trading Tuesday, while U.S. stock markets were mixed as investors saw fresh inflation data from both countries. The S&P/TSX composite index was down 144.71 points at 27,054.14. In New York, the Dow Jones industrial average was down 436.36 points at 44,023.29. The S&P 500 index was down 24.80 points at 6,243.76, while the Nasdaq composite was up 37.47 points at 20,677.80. 'Generally, markets have been pretty cautious with all the trade tensions heating up again,' said Kim Inglis, a senior portfolio manager at Raymond James, in an interview. Stocks also felt pressure from a report showing inflation in the United States accelerated to 2.7 per cent last month from 2.4 per cent in May. Economists pointed to increases in prices for clothes, toys and other things that tend to get imported from other countries. The latest U.S. inflation update hurt Wall Street's hopes for lower interest rates. Inflation data from Statistics Canada released Tuesday showed Canada's annual pace of inflation accelerated to 1.9 per cent in June. 'Inflation is obviously something everybody's looking at in general, because there's a lot of concern that the ongoing trade, tariff situation will end up impacting that,' Inglis said. Trade tensions are also something impacting the performance of the TSX, she said. 'Even with regards to the tariffs, this is something that would weigh on the Canadian markets for sure. And Prime Minister Carney came out and said that it's unlikely that Canada is going to have a trade deal with the U.S. that's going to be completely tariff-free,' she said. 'There are some negative headlines there that are going to impact things overall in terms of sentiment for the day.' A trade deal with the United States will likely include some tariffs, Prime Minister Mark Carney indicated on Tuesday ahead of a meeting with his cabinet. On Wall Street, tech stocks were the outliers and rose after Nvidia said the U.S. government had assured it that licenses will be granted for its H20 chip again and that deliveries will hopefully begin soon. Nvidia's four per cent gain was by far the strongest force pushing upward on the S&P 500. 'In general, there's so much interest in AI, and AI is really showing up in all areas of our lives. It's becoming something that's being inserted into virtually every product these days,' Inglis said. 'So I don't think that there is going to be any sort of slowing with that. The demand is there for AI, investments are pouring into AI to build that out.' Stocks of big U.S. banks, meanwhile, were mixed following their latest earnings reports. JPMorgan Chase slipped 0.7 per cent despite reporting a stronger profit than analysts expected, as CEO Jamie Dimon warned of risks to the economy because of tariffs and other concerns. Citigroup rose 3.7 per cent following its better-than-expected profit report. But Wells Fargo fell 5.5 per cent following its own, as it trimmed its forecast for an important way that it makes money. The Canadian dollar traded for 72.94 cents US compared with 73.03 cents US on Monday. The September crude oil contract was down 44 cents US at US$65.37 per barrel. The August gold contract was down US$22.40 at US$3,336.70 an ounce. This report by The Canadian Press was first published July 15, 2025. Companies in this story: (TSX:GSPTSE, TSX:CADUSD) Note to readers:This is a corrected story. A previous version had an incorrect settle price for crude oil.
